News

Emtricitabine and tenofovir alafenamide are from Gilead Sciences, while rilpivirine is from Janssen Sciences Ireland UC. Odefsey is Gilead’s second TAF-based regimen to secure FDA approval and represents

ProStrakan agreed to pay AstraZeneca $70m upfront for the rights in the European Union as well as Iceland, Norway, Switzerland, and Liechtenstein. AstraZeneca will also receive future tiered

The guidance addresses donation of HCT/Ps from both living and deceased donors, including donors of umbilical cord blood, placenta, or other gestational tissues. The new guidance is a

The results from this study confirmed CTP-656’s superior pharmacokinetic profile to Kalydeco as was previously reported from Concert’s single ascending dose trial, which demonstrated favorable pharmacokinetic properties with

The LAVOLTA I-II studies were identical, double-blind, randomised, multicentre, placebo-controlled studies that evaluated the efficacy and safety of lebrikizumab in people with severe asthma. LAVOLTA I met its

RespireRx plans to start a phase 2A clinical trial by the end of this month to confirm the ability of CX1739 to antagonize the respiratory depressant effects of

The trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma failed to hit its primary target. AstraZeneca senior vice president, head of

Lice are a nuisance and causes embarrassment for many, however carry no serious harm. While lice have built a resistance for over-the-counter products there are several prescription products

NS2 is an aldehyde-binding small molecule based on a platform technology that centers on trapping aldehydes, which are toxic and pro-inflammatory mediators of several diseases. It lowers aldehyde